MWNA
EPZM

Marshall Wace North America’s Epizyme, Inc EPZM Stock Holding History

Marshall Wace North America’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,358
Closed -$123K – 1687
2020
Q3 		$123K Sell
10,358
-58,570
-85% -$785K ﹤0.01% 1154
2020
Q2 		$1.11M Buy
68,928
+29,016
+73% +$506K 0.01% 732
2020
Q1 		$619K Buy
+39,912
New +$857K ﹤0.01% 713
2019
Q2 		– Sell
-18,942
Closed -$235K – 1766
2019
Q1 		$235K Buy
+18,942
New +$212K ﹤0.01% 950
2018
Q3 		– Sell
-138,239
Closed -$1.87M – 1502
2018
Q2 		$1.87M Buy
+138,239
New +$2.15M 0.01% 780

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Marshall Wace North America's EPZM Position: Q4 2020 in Review

Marshall Wace North America sold out of Epizyme, Inc (EPZM) in Q4 2020, closing a stake of 10,358 shares — an estimated $123K sold.

Marshall Wace North America first reported a position in EPZM in Q2 2018 and held it in 5 quarters. The position peaked at $1.87M in Q2 2018. 138 funds tracked by Wall St. Rank hold EPZM as of Q4 2020.

  • Marshall Wace North America reported no remaining Epizyme, Inc position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 10,358 Epizyme, Inc shares in Q4 2020, an estimated $123K.
  • Marshall Wace North America first reported a position in Epizyme, Inc in Q2 2018 and held it in 5 quarters.
  • Marshall Wace North America's Epizyme, Inc position peaked at $1.87M in Q2 2018.
  • 138 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.